Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Primary Purpose
Cholangiocarcinoma, Biliary Stricture, Biliary Obstruction
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Photodynamic Therapy
Sponsored by
About this trial
This is an interventional supportive care trial for Cholangiocarcinoma focused on measuring Cholangiocarcinoma, Biliary Stricture, Biliary obstruction, Bile Duct Cancer, PDT, Photodynamic Therapy, Plastic optic Diffuser, Laser
Eligibility Criteria
Inclusion Criteria:
- Patient with cholangiocarcinoma
- Patient is age 18 years or older
- Patient is receiving Photodynamic therapy with stent(s) placement as part of their original treatment plan
- Patients must have adequate coagulation as defined below:
Patient's INR ≤ 2 within 30 days of treatment Patient's platelets > 50,000/cmm within 30 days of treatment
Exclusion Criteria:
- Subject has acute porphyria. Subjects exhibiting neurologic or cutaneous symptoms will undergo urinary delta-aminolevulinic acid and porphobilinogen dosage tests to determine severity.
- Subject is pregnant.
- Subject is allergic to Photofrin.
- Subject has uncorrected coagulopathy
- Subject is unstable for ERCP
Sites / Locations
- Weill Cornell Medical CollegeRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PDT Group
Arm Description
Subjects who receive Photodynamic therapy with plastic optic diffuser.
Outcomes
Primary Outcome Measures
Efficacy Profile
To assess the efficacy of a plastic cylindrical fiber optic diffuser (Pioneer Optics) in photodynamic therapy for the management of Cholangiocarcinoma by visualization of visible necrosis of target tissue in bile ducts after the application of the device.
Secondary Outcome Measures
Safety Profile
To assess the the number and intensity of adverse events occurring due to the application of the research device.
Full Information
NCT ID
NCT01755013
First Posted
March 1, 2012
Last Updated
February 16, 2017
Sponsor
Weill Medical College of Cornell University
1. Study Identification
Unique Protocol Identification Number
NCT01755013
Brief Title
Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Official Title
Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 2012 (undefined)
Primary Completion Date
January 22, 2018 (Anticipated)
Study Completion Date
March 22, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Weill Medical College of Cornell University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Successful palliation of biliary obstruction is the main goal for reducing morbidity and mortality in patients with biliary disease and biliary obstruction related to cholangiocarcinoma. Surgical intervention for the sale is unfortunately complicated by a 30-day postoperative mortality rate of between 7 and 24%. Moreover, because of recovery time the quality of life following surgery is only improved in a minority. At present endoscopic insertion of a plastic or metal stent is the method of choice to relieve obstructive jaundice without the high morbidity and mortality associated with surgery. But this relief is unfortunately temporary since stents tend to become obstructed and the fact that effective biliary drainage in the proximal lesion is challenging.
Photodynamic Therapy (PDT) is a new therapeutic approach that specifically targets neoplastic cells. This therapy involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. A randomized controlled trial study by Ortner et all confirmed the significant advantage of PDT with regard to relief of jaundice, quality of life, and survival.
In photodynamic therapy (PDT) the uniform distribution of externally applied light is desirable but often difficult to achieve. An optical fiber tip producing cylindrical or lateral light emission can facilitate the application of laser energy by direct implantation of the tip into solid tumors. However, currently used FDA approved glass diffusers used in standard of care PDT might break in the bile ducts causing injury since they are not meant to be used within bile ducts through an endoscope or choledochoscope. Hence, there is a need to evaluate and introduce more efficient and safe non-glass cylindrical optic fiber diffuser for photo dynamic therapy in the bile ducts. Recent studies have shown that the Pioneer plastic optic diffuser is safe and effective in photodynamic therapy, it can be also used via a choledochoscope. We aim to add to the clinical evidence by conducting an open label observational study trial using this fiber optic diffuser during photo dynamic therapy in the bile ducts.
Detailed Description
Cholangiocarcinoma (CCA) is the second most common malignancy arising within the liver, and the association of this malignant condition with high morbidity and mortality is well recognized. It originates from the epithelium of bile ducts or ductules. Two types have been described: the peripheral type occurring in the parenchyma of the liver and the central type occurring within or related to the major bile ducts. Surgery can offer a curative chance, but only a minority of patients are candidates for this therapy at initial presentation since most patients are found with an unresectable tumor.
In unresectable cases, the median survival is 6 months. Since morbidity and mortality from CCA occurs because of biliary obstruction, successful palliation of that complication is the main goal in these patients. Surgical biliary bypass can be offered in order to prolong life and relieve symptoms. This intervention is unfortunately complicated by 30-day postoperative mortality rate between 7 and 24%. Moreover, the quality of life following surgery is only improved in a minority because of the time needed to recover from surgery.
Endoscopic biliary stenting during endoscopic retrograde cholangiopancreatography (ERCP) offers relief from obstructive jaundice without the high morbidity and mortality associated with surgery. In addition, a study by Luman et al even showed significant improvement in emotional, cognitive and global health scores following stenting. But this relief is unfortunately temporary since stents tend to become obstructed.
Local therapies including iridium brachytherapy and photodynamic therapy (PDT) may prevent or postpone these problems.
For more information about PDT, please see the 'Citations' section.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholangiocarcinoma, Biliary Stricture, Biliary Obstruction, Bile Duct Cancer
Keywords
Cholangiocarcinoma, Biliary Stricture, Biliary obstruction, Bile Duct Cancer, PDT, Photodynamic Therapy, Plastic optic Diffuser, Laser
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PDT Group
Arm Type
Experimental
Arm Description
Subjects who receive Photodynamic therapy with plastic optic diffuser.
Intervention Type
Procedure
Intervention Name(s)
Photodynamic Therapy
Other Intervention Name(s)
PDT, Laser
Intervention Description
Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
Primary Outcome Measure Information:
Title
Efficacy Profile
Description
To assess the efficacy of a plastic cylindrical fiber optic diffuser (Pioneer Optics) in photodynamic therapy for the management of Cholangiocarcinoma by visualization of visible necrosis of target tissue in bile ducts after the application of the device.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Safety Profile
Description
To assess the the number and intensity of adverse events occurring due to the application of the research device.
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with cholangiocarcinoma
Patient is age 18 years or older
Patient is receiving Photodynamic therapy with stent(s) placement as part of their original treatment plan
Patients must have adequate coagulation as defined below:
Patient's INR ≤ 2 within 30 days of treatment Patient's platelets > 50,000/cmm within 30 days of treatment
Exclusion Criteria:
Subject has acute porphyria. Subjects exhibiting neurologic or cutaneous symptoms will undergo urinary delta-aminolevulinic acid and porphobilinogen dosage tests to determine severity.
Subject is pregnant.
Subject is allergic to Photofrin.
Subject has uncorrected coagulopathy
Subject is unstable for ERCP
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michel Kahaleh, MD
Phone
646-962-4797
Email
mkahaleh@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Monica Gaidhane, MD, MPH
Phone
646-962-4796
Email
mog2012@med.cornell.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel Kahaleh, MD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Weill Cornell Medical College
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michel Kahaleh, MD
Phone
646-962-4797
Email
mkahaleh@gmail.com
First Name & Middle Initial & Last Name & Degree
Monica Gaidhane, MD, MPH
Phone
646-962-4796
Email
mog2012@med.cornell.edu
First Name & Middle Initial & Last Name & Degree
Michel Kahaleh, MD
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
No sharing of IPD
Citations:
PubMed Identifier
21512706
Citation
Talreja JP, DeGaetani M, Sauer BG, Kahaleh M. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment. Photochem Photobiol Sci. 2011 Jul;10(7):1233-8. doi: 10.1039/c0pp00259c. Epub 2011 Apr 21.
Results Reference
background
PubMed Identifier
21173912
Citation
Richter JA, Kahaleh M. Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc. 2010 Nov 16;2(11):357-61. doi: 10.4253/wjge.v2.i11.357.
Results Reference
background
PubMed Identifier
21103297
Citation
Talreja JP, Kahaleh M. Photodynamic therapy for cholangiocarcinoma. Gut Liver. 2010 Sep;4 Suppl 1(Suppl 1):S62-6. doi: 10.5009/gnl.2010.4.S1.S62. Epub 2010 Sep 10.
Results Reference
background
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/21512706
Description
Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment. Talreja JP, DeGaetani M, Sauer BG, Kahaleh M.
URL
http://www.ncbi.nlm.nih.gov/pubmed/21173912
Description
Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. Richter JA, Kahaleh M.
URL
http://www.ncbi.nlm.nih.gov/pubmed/21103297
Description
Photodynamic therapy for cholangiocarcinoma. Talreja JP, Kahaleh M.
Learn more about this trial
Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
We'll reach out to this number within 24 hrs